NASDAQ Soins de santé Biotechnologie SPRY

ARS Pharmaceuticals, Inc.

$ 9.65 -2.53 %

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

CEO: Richard E. Lowenthal - https://ars-pharma.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$25.5 164.25 %

Recommandation

Hold

DCF

$ -4.41

Loading data...

SPRY vs S&P500

Loading data...

No data available.

Quick ratio

4.77

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-4.82

may indicate that the company is undervalued or has poor growth prospects.

EPS

-2.00

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-153.61 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-85.03 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

7.77

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

1.57

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-1.77

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
-0.27 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.49 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.34 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.